Skip to main content
SpringerLink
Log in
Book cover

Cerebral Ischemia and Calcium pp 16–28Cite as

Pharmacological Activities of Calcium Antagonists: Therapeutic Applications and Adverse Reactions

  • Conference paper

  • 156 Accesses

Abstract

Calcium antagonists or calcium entry blockers are considered to be a breakthrough in the drug treatment of cardiovascular disease, while their importance as tools in fundamental research is generally recognized as well. More recently, certain types of calcium antagonists have been studied as potentially useful drugs in the treatment of neurological disorders, such as migraine, cerebral ischemia and hypoxia, certain forms of vertigo, epilepsy, and subarachnoid hemorrhage.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Betz E, Deck K, Hoffmeister F (eds) (1985) Nimodipine. Pharmacological and clinical properties. Proceedings of the 1st International Nimotop-Symposium, Munich 1984. Schattauer, Stuttgart

    Google Scholar 

  2. Boddeke HWGM, Heynis JB, Jonkman FAM, Van Zwieten PA (1986) Characterization of calcium entry blockers in isolated guinea-pig hearts; cardiodepressant activity of flunarizine. Br J Pharmacol 89:615

    Google Scholar 

  3. Bou J, Llenas J, Massingham R (1983) Calcium entry blocking drugs, “calcium antagonists” and vascular smooth muscle function. J Auton Pharmacol 3:219–232

    Article  PubMed  CAS  Google Scholar 

  4. Borgers M. Personal communication

    Google Scholar 

  5. Braunwald E (1982) Mechanism of action of calcium channel blocking agents. N Engl J Med 307:1618–1627

    Article  PubMed  CAS  Google Scholar 

  6. Bussey HF, Talbert RL (1984) Promising uses of calcium channel blocking agents. Pharmacotherapy 4:137–143

    PubMed  CAS  Google Scholar 

  7. Fleckenstein A (1977) Specific pharmacology of calcium in the myocardium cardiac pacemaker and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149–166

    Article  CAS  Google Scholar 

  8. Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects. Wiley, New York

    Google Scholar 

  9. Gelmers HJ (1984) The effects of nimodipine on the clinical course of patients with acute ischeemic stroke. Acta Neurol Scand 69:232–239

    Article  PubMed  CAS  Google Scholar 

  10. Glossmann H, Ferry DR, Lubbecke F, Mewes R, Hofmann F (1982) Calcium channels: direct identification with radioligand binding studies. Trends Pharmacol Sci 3:431–437

    Article  CAS  Google Scholar 

  11. Glossmann H, Goll A, Rombusch M, Ferry DR (1985) Molecular pharmacology of Ca2+-channels: receptor binding studies. In: Betz A, Deck K, Hoffmeister A (eds) Nimodipine; pharmacological and clinical properties. Schattauer, Stuttgart, pp 57–76

    Google Scholar 

  12. Godfraind T, Miller RC, Socrates Lima J (1982) Selective α1 and α2-adrenoceptor agonist-induced contractions and 45Ca-fluxes in the rat isolated aorta. Br J Pharmacol 77:597–604

    PubMed  CAS  Google Scholar 

  13. Godfraind T, Herman A, Wellens H (1984) Calcium entry blockers in cardiovascular and cerebral dysfunctions. Nijhoff, Den Haag

    Book  Google Scholar 

  14. Gray Ellrodt A, Singgh BN (1983) Clinical applications of slow channel blocking compounds. Clin Pharmacol Ther 23:1–43

    Google Scholar 

  15. Hartmann A, Van Zwieten PA (1986) Pharmacological aspects and neurological potential of calcium entry blockers. XIIIth World Congress of Neurology, Hamburg 1985. Eur Neurol 25(Suppl 1):1–126

    Google Scholar 

  16. Jonkman FAM, Boddeke HWGM, Van Zwieten PA (1986) Protective activity of calcium entry blockers against ouabain intoxication in anaesthetized guinea pigs. J Cardiovasc Pharmacol 8:1009–1013

    Article  PubMed  CAS  Google Scholar 

  17. Kazda SR (1982) Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir 63:259–265

    Article  CAS  Google Scholar 

  18. Labrid C, Grosset A, Dureng G, Mironneau J, Duchêne-Marillaz P (1979) Some membrane interactions with bepridil, a new antianginal agent. J Pharmacol Exp Ther 211:546–554

    PubMed  CAS  Google Scholar 

  19. Lederballe Pedersen O, Christensen NJ, Ramsch KD (1980) Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 2:357–361

    Article  Google Scholar 

  20. Mannhold R, Rodenkirchen R, Bayer R (1982) Qualitative and quantitative structure-activity relationships of specific Ca-antagonists. Prog Pharmacol 5:25–52

    CAS  Google Scholar 

  21. Marshall RJ, Winslow E, Lamar JC, Apoil E (1984) Bepridil. In: Scriabine A (ed) New drugs annuals: cardiovascular drugs, vol 2. Raven, New York, pp 157–176

    Google Scholar 

  22. Van Meel JCA, De Jonge A, Wilffert B, Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1981) Organic and inorganic calcium antagonists reduce vasoconstriction in vivo mediated by postsynaptic α2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 316:288–293

    Article  PubMed  Google Scholar 

  23. Van Meel JCA, Towart R, Timmermans PBMWM, Van Zwieten PA (1983) Correlation between the inhibitory activities of calcium antagonists on vascular smooth muscle constriction in vitro after depolarisation and in vivo after α2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 322:34–37

    Article  PubMed  Google Scholar 

  24. Nayler WG, Poole-Wilson P (1981) Calcium antagonists: definition and mode of action. Basic Res Cardiol 76:1–15

    Article  PubMed  CAS  Google Scholar 

  25. Nayler WG (1980) Calcium antagonists. Eur Heart J 1:225–237

    PubMed  CAS  Google Scholar 

  26. Van Nueten JM, Janssen PAJ (1973) Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther 204:37–55

    PubMed  Google Scholar 

  27. Van Nueten JM, Van Beek J, Janssen PAJ (1978) Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther 232:42–52

    PubMed  Google Scholar 

  28. Van Nueten JM, Vanhoutte PM (1982) Calcium entry blockers and vasospasm. In: Vanhoutte PM, Leusen I (eds) Vasodilatation. Raven, New York, pp 459–468

    Google Scholar 

  29. Overweg J, Ashton D, De Beukelaar F, Binnie CD, Wauquier A, Van Wieringen A (1986) Add-on therapy in epilepsy with calcium entry blockers. Eur J Neurol 25:93–101

    Google Scholar 

  30. Paci A, Ottaviono B, Trenta A, Iannone G, Acuto G, Carosi M. Treatment of acute ischemic cerebral infarction with nimodipine (BAY e 9736). Cited in ref. 47

    Google Scholar 

  31. Packer M, Frishman WH (1984) Calcium channel antagonists in cardiovascular disease. Appleton-Century-Crofts, Norwalk (Conn), pp 225–269

    Google Scholar 

  32. Paoletti R, Vanhoutte PM (1987) International symposium on calcium antagonists. Pharmacology and clinical research. New York City

    Google Scholar 

  33. Peters T (1983) “Calcium-Antagonismus”. Ein einheitlicher Begriff für uneinheitliche Wirkmechanismen. Med Klinik 78:368–375

    CAS  Google Scholar 

  34. Peters T (1986) Calcium in physiological and pathophysiological cell function. Eur Neurol 25(Suppl l):27–44

    Article  PubMed  CAS  Google Scholar 

  35. Rodenkirchen R, Bayer R, Mannhold R (1982) Specific and nonspecific analysis of cardiodepressive drugs. Prog Pharmacol 5:9–23

    CAS  Google Scholar 

  36. Rodenkirchen R, Bayer R, Steiner R, Bossert F, Meyer H, Möller E (1979) Structure-activity studies on nifedipine in isolated cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 310:69–78

    Article  PubMed  CAS  Google Scholar 

  37. Schwartz A, Triggle DJ (1984) Cellular action of calcium channel blocking drugs. Ann Rev Med 35:325–339

    Article  PubMed  CAS  Google Scholar 

  38. Spedding M (1985) Calcium antagonist subgroups. Trends Pharmacol Sci 6:109–114

    Article  CAS  Google Scholar 

  39. Spedding M (1987) Three types of Ca2+-channels explain discrepancies. Trends Pharmacol Sci 8:115–117

    Article  Google Scholar 

  40. Tanaka K, Gotoh F, Muranratsu F et al. (1980) Effects of nimodipine (BAY e 9736) on cerebral circulation in cats. Arzneimittelforschung 26:2172–2176

    Google Scholar 

  41. Triggle DJ, Swamy VC (1983) Calcium antagonists. Some chemical-pharmacologic aspects. Circ Res 52(Suppl I): 17–28

    CAS  Google Scholar 

  42. Vanhoutte PM, Bohr DF (1981) Calcium entry blockers and the cardiovascular system. Fed Proc 40:2851

    Google Scholar 

  43. Wauquier A, Edmonds HC, Van den Broek WAE, Melis W, Van Loon J (1985) Effects of flunarizine on recovery of cerebral function following cardiac arrest. Neuropsychobiology 13:147–151

    Article  PubMed  CAS  Google Scholar 

  44. Van Zwieten PA (1985) Calcium antagonists — terminology, classification and comparison. Arzneimittelforschung 35:298–301

    PubMed  Google Scholar 

  45. Van Zwieten PA (1986) Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers. Eur Neurol 25(Suppl 1):57–67

    Article  PubMed  Google Scholar 

  46. Van Zwieten PA (1985) Drug targets in unstable angina. In: Hugenholtz PG, Goldman BS (eds) Unstable angina, current concepts and management. Schattauer, Stuttgart, pp 151–157

    Google Scholar 

  47. Van Zwieten PA, Timmermans PBMWM (1985) Pharmacological basis of the antihypertensive action of calcium entry blockers. J Cardiovasc Pharmacol 7:S11–S17

    Article  PubMed  Google Scholar 

  48. Van Zwieten PA, Schönbaum E (1983) Calcium antagonists and blood vessels. Prog Pharmacol 5:1–142

    Google Scholar 

  49. Van Zwieten PA, Van Meel JCA, Timmermans PBMWM (1983) Pharmacological basis of the therapeutic effect of calcium entry blockers. Interaction with vascular α-adrenoceptors. Hypertension 5(Suppl II):II–8–II–17

    Google Scholar 

  50. Van Zwieten PA, Timmermans PBMWM, Van Heiningen PNM (1987) Receptor subtypes involved in the action of calcium antagonists. J Cardiovasc Pharmacol 5(Suppl 4):S21–S28

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacotherapy, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, NL-1105 AZ, Amsterdam, The Netherlands

    P. A. van Zwieten

Authors
  1. P. A. van Zwieten
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Universitätsklinik, Sigmund-Freud-Str. 25, D-5300, Bonn 1, Germany

    Alexander Hartmann

  2. Physiologisches Institut der Universität, Im Neuenheimer Feld 326, D-6900, Heidelberg, Germany

    Wolfgang Kuschinsky

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

van Zwieten, P.A. (1989). Pharmacological Activities of Calcium Antagonists: Therapeutic Applications and Adverse Reactions. In: Hartmann, A., Kuschinsky, W. (eds) Cerebral Ischemia and Calcium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85863-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85863-5_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85865-9

  • Online ISBN: 978-3-642-85863-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation